Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) CEO John Craig Thompson acquired 10,400 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was purchased at an average cost of $1.43 per share, for a total transaction of $14,872.00. Following the completion of the purchase, the chief executive officer now directly owns 11,298 shares of the company’s stock, valued at $16,156.14. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) traded down 4.17% during mid-day trading on Thursday, hitting $1.38. 366,102 shares of the company’s stock were exchanged. Anthera Pharmaceuticals, Inc. has a 12 month low of $1.20 and a 12 month high of $27.36. The stock’s 50 day moving average price is $1.39 and its 200-day moving average price is $1.24. The stock’s market cap is $15.05 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.09) by $1.12. Equities analysts expect that Anthera Pharmaceuticals, Inc. will post ($3.68) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/07/anthera-pharmaceuticals-inc-anth-ceo-purchases-14872-00-in-stock.html.

A number of brokerages recently issued reports on ANTH. Jefferies Group LLC reissued a “hold” rating and issued a $2.25 price objective on shares of Anthera Pharmaceuticals in a research note on Monday, May 15th. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. Finally, ValuEngine cut shares of Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $10.11.

Several institutional investors have recently bought and sold shares of the company. UBS Group AG raised its position in shares of Anthera Pharmaceuticals by 9.9% during the 1st quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Anthera Pharmaceuticals by 1,376.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares in the last quarter. Finally, Sabby Management LLC raised its position in shares of Anthera Pharmaceuticals by 1,809.7% during the 1st quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares in the last quarter. Hedge funds and other institutional investors own 27.26% of the company’s stock.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.